NanoViricides' leading drug candidate, NV-387, is a broad-spectrum antiviral targeting respiratory viruses, designed to mimic sulfated proteoglycans that viruses use for cell attachment, making it resistant to viral escape.

Success in treating MPox with NV-387 could pave the way for FDA approval as a Smallpox therapeutic, unlocking potential government and international stockpiling contracts valued at over $10 billion.

NV-387's broad activity could eliminate the need for frequent vaccine updates due to viral mutations, potentially saving billions annually and allowing immediate antiviral treatment upon infection.

NV-387 is progressing toward Phase II trials for MPox, with promising animal data showing effectiveness against respiratory viruses like RSV, Influenza A, coronaviruses, and others, including smallpox and measles.

The drug has demonstrated complete cures in animal models for RSV and high efficacy in lethal models for MPox and measles, which are significant health threats with no current approved treatments.

NanoViricides will present at the LSX World Congress 2025 in Boston on September 17th, where the company's leadership will discuss its drug pipeline, licensing opportunities, and the revolutionary potential of broad-spectrum antivirals.

The LSX Congress provides a platform for biotech and pharma leaders to network and showcase innovations, with the event taking place at the Boston Convention Center.

The presentation will include updates on licensing strategies and market opportunities, emphasizing the potential of nanotechnology-based broad-spectrum antivirals.

NanoViricides' platform employs innovative nanomaterials designed to overcome viral resistance, enabling drug rescue, oral delivery, and targeted tissue-specific treatments, increasing efficacy and reducing side effects.

Beyond its current pipeline, the company is developing treatments for herpes, viral eye diseases, and other pathogens, with future licensing plans for RSV, poxviruses, and enteroviruses.

The company's technology is licensed from TheraCour Pharma, granting broad rights for antiviral development against diseases like HIV, hepatitis, rabies, Ebola, and various influenza strains.

NanoViricides is also developing candidates like NV-HHV-1 for herpesviruses and NV-HIV-1, designed to prevent viral escape by targeting conserved entry sites, with efficacy shown in animal models.